Navigation Links
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
Date:9/26/2008

eceived feedback from the CHMP that there are no major objections remaining related to chemistry, manufacturing and controls (CMC)."

Mr. Walbert continued, "While we have satisfactorily addressed issues related to the positive benefit/risk assessment reached at the oral explanation meeting with the CHMP in January 2008, we have been invited by the CHMP to meet with SAG-O and CHMP in November to address certain open issues arising from the assessment by the Rapporteur and Co-Rapporteur. We welcome the opportunity to present to both the SAG-O and CHMP to complete the L-MTP-PE MAA review and we remain confident that L-MTP-PE provides a significant overall survival benefit for osteosarcoma patients and meets an important unmet treatment need."

With the final CHMP opinion now anticipated in November, IDM Pharma expects a final decision from the European Commission in the first quarter of 2009. If approved for Marketing Authorization by the European Commission, L-MTP-PE will be the first treatment in more than 20 years approved for patients with osteosarcoma.

In January 2008, the Company announced that, following presentation of data at an oral explanation hearing, the CHMP determined in a non-binding opinion that L-MTP-PE suggested a possible clinical benefit in terms of survival and granted the Company a clock-stop, or time extension to allow IDM Pharma additional time to respond to questions regarding the MAA. At that time, the CHMP requested clarification of the existing data in order to gain assurance about the quality of the data before drawing any final conclusions from the data presented. In addition, the Company was required to address a number of remaining questions relating to CMC.

In April 2008, the European regulatory authorities conducted an inspection of the COG to assess the quality of the overall survival data from the 2006 confirmatory database included in the Company's applications for regulatory approval, and to review GCP c
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
2. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
3. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
4. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
5. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
8. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
9. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
10. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- STAAR Surgical Company (NASDAQ: STAA ) ... and delivery systems for the eye today reported revenue ... $20.0 million, a 10% increase over $18.2 million reported ... currency basis, revenues grew 11% during the second quarter ... The effect of foreign currency exchange reduced sales by ...
(Date:7/31/2014)... Xencor Inc. (NASDAQ: XNCR ... antibodies for the treatment of autoimmune diseases, asthma ... results for the second quarter ended June 30, 2014 ... "In the second quarter, we presented ... International Conference (ATS) demonstrating three novel mechanisms of ...
(Date:7/31/2014)... , July 31, 2014  Alexza Pharmaceuticals, Inc. ... update on its pipeline and new product development ... to initiate a Phase 2a study of AZ-002 ... for the management of patients with acute repetitive ... Staccato -based product candidates for development - AZ-008 ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6
... Sept. 17 Pharmasset, Inc.,(Nasdaq: VRUS ) management ... held from September 22-25, 2008 at the Grand Hyatt ... Officer,will provide an overview of the company on Wednesday, ... To access a live webcast of Mr. Price,s ...
... CT Colonography Trial Raise Questions for,Patients, OAK ... CT Colonography Trial, published in the September 18 ... improvements in the technology,s,ability to diagnose intermediate- to ... testing is not as effective in diagnosing small ...
Cached Medicine Technology:Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th 2ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 2ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 3ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 4ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 5
(Date:8/1/2014)... The Cardiovascular Research Foundation (CRF) has announced ... will be presented at next month,s Transcatheter Cardiovascular ... premier educational meeting specializing in interventional cardiovascular medicine, ... at the Walter E. Washington Convention Center in ... TCT often direct the course of patient therapies. ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 ... Market Outlook to 2020", provides key market ... market. The report provides value, in millions ... average prices (in US dollars) within market ... Ultrasonic Generators and Argon Plasma Coagulation Generators. ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 In today’s ... overall development of an individual. Hence, these methods need ... and employability skills can be inculcated. In this age ... boost to these conventional methods. Thus, learning management systems ... methodologies. , As of now, these are proving ...
(Date:8/1/2014)... Aug. 1, 2014 (HealthDay News) -- Women who serve ... alcohol than their civilian peers, a new study suggests. ... to consume alcohol. However, these researchers found that women ... men. This may be due to concerns about sexual ... use is tightly linked to sexual assault, both within ...
(Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Roaming the ... preserved mummy became famous as the "Ice Man" no doubt ... of that may still not have shielded the Ice Man, ... A human,s genetic risk for atherosclerosis, or "hardening of the ... thousands of years ago, a new study finds. ...
Breaking Medicine News(10 mins):Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 2Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 3Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 4Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 2Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 3Health News:North America Learning Management System Market is Expected to Reach $5.13 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Learning Management System Market is Expected to Reach $5.13 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Learning Management System Market is Expected to Reach $5.13 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Women in Military Drink Less Than Civilians, Report Shows 2Health News:'Ice Man' Mummy May Have Been at Risk of Heart Disease 2
... Structural biologists at Cold Spring Harbor Laboratory (CSHL) have ... for an allosteric inhibitor in a subtype of the ... cells. The newly discovered binding site -- ... because it is a potential target for drugs that ...
... , THURSDAY, June 16 (HealthDay News) -- ... else is making many people with middle and low ... grown a lot in the U.S., especially since the ... University of Virginia, said in news release from the ...
... By Denise Mann HealthDay Reporter , WEDNESDAY, June ... some people stopped flying out of fear of catching the virus ... new study shows that the "danger zone" for flu transmission is ... had been thought that this hot zone was much larger, according ...
... WEDNESDAY, June 15 (HealthDay News) -- Men who struggle with ... new study suggests. The study, by researchers from ... found that impotence, or erectile dysfunction, was more common among ... frequent the symptoms of the sleep disorder the higher the ...
... HealthDay Reporter , TUESDAY, June 14 (HealthDay News) -- For ... simple as sleeping on their left side, New Zealand researchers ... sleep on their left side had twice the risk of ... increase in risk [from right-sided sleeping] is small for the ...
... used cutting-edge stem cell technology to correct a genetic ... on a promising path that may one day lead ... diseases such as macular degeneration and retinitis pigmentosa which ... in an advance online publication of the journal ...
Cached Medicine News:Health News:CSHL structural biologists reveal novel drug binding site in NMDA receptor subunit 2Health News:Study Finds Two-Seat 'Hot Zone' for Flu Spread on Planes 2Health News:Study Finds Two-Seat 'Hot Zone' for Flu Spread on Planes 3Health News:Study Finds Two-Seat 'Hot Zone' for Flu Spread on Planes 4Health News:Impotence Linked to Restless Legs Syndrome 2Health News:Could Sleeping on Left Side Help Prevent Stillbirth? 2Health News:Could Sleeping on Left Side Help Prevent Stillbirth? 3Health News:Researchers report progress using iPS cells to reverse blindness 2